A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients
A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients
The purpose of this study is to determine whether post-operative concurrent chemoradiation
 with paclitaxel/carboplatin is effective and safe in the treatment of high risk cervical
 cancer patients.
Stage Ib to IIa cervical cancer can be treated effectively with either radioterapy or radical
 hysterectomy plus pelvic lymph node dissection. However, several pathological risk factors
 have been identified to compromise the treatment outcome. They include lymph node metastasis,
 the involvement of vaginal resection margin, and the parametrial invasion. In these patients,
 postoperative RT is commonly recommended and has been demonstrated to improve the local
 control, but not survival rate. Recently, It is reported that the additon of concurrent
 chemotherapy to postoperative RT reduced pelvic failures and enhanced progression free
 survival. In addition, paclitaxel/platinum combination chemotherapy was demonstrated to have
 superior progression-free survical over single agent platinum in a primary treatment of stage
 IV or recurrent cervical cancer.

 Based on this obseration, we evaluated the efficacy and safety of CCRT with
 paclitaxel/carboplatin in patients with postoperative high risk factors.
Inclusion Criteria:

 -  Patients undertaken radical hysterectomy with diagnosis of invasive cervical cancer
 Ib-IIa (non-small cell type)

 -  Patients must have at least one of the following risk factors; pelvic lymph node
 involvemet, involvement of vaginal resection margin,parametrial invasion.

 -  Patients must have a GOG performance of 0, 1, or 2.

 -  Patients must have expected life span over 6 months.

 Exclusion Criteria:

 -  Patients with peripheral neurotoxicity over grade 2 in CTC criteria.

 -  Patients with history of chemotherapy or radiation treatment.

 -  Patients with histologicallly proven or highly suspected metastasis to paraaortic
 lymph node.

 -  Patients with history of hypersensitive reaction to platinum agent.